• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Cencora Inc.

    5/30/25 4:11:02 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    SD 1 formsdcoverpage.htm SD Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM SD

    SPECIALIZED DISCLOSURE REPORT

    Cencora, Inc.
    (Exact name of the registrant as specified in its charter)

    Delaware001-16671
    (State or other jurisdiction of incorporation or organization)(Commission File Number)

    1 West First Avenue, Conshohocken PA19428-1800
    (Address of principal executive offices)(Zip code)

    Elizabeth S. Campbell 610-727-7000
    (Name and telephone number, including area code, of the
    person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

    ☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    o Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ________.


    Section 1 - Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure

    This Specialized Disclosure Report on Form SD (this “Form SD”) of Cencora, Inc. (the “Company”) and the associated Conflict Minerals Report are filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024.




    A copy of the Company’s Conflict Minerals Report is attached hereto as Exhibit 1.01, and is publicly available on the Company’s website at investor.cencora.com. The Company's website and the information accessible through it are not incorporated into this Form SD and are not deemed filed with the U.S. Securities and Exchange Commission.

    Item 1.02 Exhibit

    The Conflict Minerals Report required by Item 1.01 is filed as Exhibit 1.01 hereto.


    Section 2 - Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.


    Section 3 - Exhibits

    Item 3.01 Exhibits

    The following exhibit is submitted as part of this report:

    Exhibit 1.01Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.


     SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    CENCORA, INC.
    By:/s/ Elizabeth S. CampbellDate:May 30, 2025
    Name:Elizabeth S. Campbell
    Title:Executive Vice President & Chief Legal Officer


    Get the next $COR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    More analyst ratings

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Elects Lori J. Ryerkerk to Its Board of Directors

      Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu

      5/28/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care